An observational one-year study found the therapy significantly reduced lung disease severity and prevented disease progression in children aged 6 to 11 with cystic fibrosis.
An observational one-year study found the therapy significantly reduced lung disease severity and prevented disease progression in children aged 6 to 11 with cystic fibrosis.
Read MoreHealth Canada granted market authorization for the expanded use of Trikafta to include children with cystic fibrosis ages 2-5 years who have at least one copy of the F508del mutation in the CFTR gene.
Read MoreThe FDA has approved the use of the Trikafta therapy to treat cystic fibrosis (CF) in children aged 6 to 11, making the therapy the first approved treatment for CF in the age group.
Read More
An observational study supported by the CF Foundation will monitor real-world experience with Trikafta.
Read MoreAccording to a study published in AJRCCM, Vertex Pharma’s Trikafta (elexacaftor/tezacaftor/ivacaftor) is safe and efficacious in children 6 through 11 years of age with at least one F508del-CFTR allele. The safety and...
Read More
Cleveland Clinic announced the Top 10 Medical Innovations for 2021., which include the cystic fibrosis therapeutic Trikafta (#4), and bubble CPAP technology for preemies (#6).
Read More
Clinicians say a combination of factors have led to improved therapy adherence and disease management in young cystic fibrosis patients since the outset of the novel coronavirus pandemic.
Read More
Cystic fibrosis patients being treated with a CFTR modulator had more positive outlooks on their futures, treatment plans, and healthcare professionals.
Read More
Trikafta is approved for patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the CFTR gene, which is estimated to represent 90% of the cystic fibrosis population.
Read More
Vertex Pharmaceuticals Inc has reported positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis (CF).
Read More
